Hyderabad-based Suven Pharmaceuticals (www.suven.com),
after setting up its US subsidiary (Suven Life Sciences
LLC, USA), has announced the acquisition of assets of
New Jersey-based Synthon Chiragenics Corporation (www.synthoncorp.com).
is a world leader in carbohydrate-based chiral technology
for pharmaceuticals. Synthon is the first and only company
to unlock the rich source of chirality contained in naturally
occurring carbohydrates, using its proprietary technology
to economically construct the most challenging chiral
molecules, which serve as cores for drugs being developed
in the faster-growing therapeutic areas, anti-virals,
antibiotics and anti-cancer.
is a significant step forward for Suven in its ambition
to emerge as a leading full spectrum provider of discovery
related services by 2005. Demand for a wide range of services
like clinical trials, contract research, manufacturing
and a host of other areas is set to show explosive growth
post-2005. Recent reports by PwC and E&Y estimate
the opportunity in the range of $20 billion.
through a focussed approach adopted since 1995, has emerged
as one of the leading players in custom synthesis for
NCEs. It''s strong relationship with more than 20 top global
life science companies worldwide in past nine years forms
a strategic competitive advantage as this opportunity
draws near and competition from other Indian companies
current base of 100 scientists in its R&D is expected
to grow significantly in the medium term. Suven expects
the US development centre-cum-marketing front-end to be
fully operational by December 2003 and play a vital role
in winning new R&D projects.
Life Sciences will employ four-to-six PhDs, in addition
to a small scientific and technical staff. Existence of
this front-end will enhance exposure of Suven''s R&D
capabilities in the most lucrative North American market
and pave the way for seamless transition from pre-clinical
level development to final manufacturing.
acquisition will cut time to market the services and offers
a significant boost to Suven''s chances of bagging R&D